(Total Views: 454)
Posted On: 08/30/2019 5:40:53 PM
Post# of 154868
I would not be surprised, we seem to be the Rodney Dangerfield of biotech, approval soon and near yearly lows. Example, Theratechnologies market cap went up 4x between successful p3 and drug approval.
But once the BLA is submitted I feel the investment is derisked some, at that point, we are not tied to more fund raising to get approval. The burn rate drops, significantly if they stop the mono trial with pivotal approval, and the balance sheet changes some with the FDA acceptance of the BLA; the product sitting in the warehouse RP was talking about, they can add the cost as an asset. Plus the vibe changes with some. If I had read it once, I have read it 1000 times, why can’t NP actually get something done instead of talking about it. With the BLA submission should change at least some of those perspectives. I could be wrong, but I’m looking forward to finding out one way or another.
All, imo.
But once the BLA is submitted I feel the investment is derisked some, at that point, we are not tied to more fund raising to get approval. The burn rate drops, significantly if they stop the mono trial with pivotal approval, and the balance sheet changes some with the FDA acceptance of the BLA; the product sitting in the warehouse RP was talking about, they can add the cost as an asset. Plus the vibe changes with some. If I had read it once, I have read it 1000 times, why can’t NP actually get something done instead of talking about it. With the BLA submission should change at least some of those perspectives. I could be wrong, but I’m looking forward to finding out one way or another.
All, imo.
(3)
(0)
